FDA
-
-
-
-
-
-
-
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
-
-
-
-
-
-
-
PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION
-
-
-
-
-
-
-
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymp
-
-
-
-
-
-
-
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-celĀ®) for the Treatment of Epstein-Barr Virus Positive Post-Transpl
-
-
-
-
-
-
-
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
-
-
-
-
-
-
-
ATARA Biotherapeutics (ATRA) receives Complete Response Letter for EBVALLOTM
-
-
-
-
-
-
-
ATARA Biotherapeutics (ATRA) Submits Tabelecleucel BLA for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
-
332,962 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


